Literature DB >> 12676952

The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung.

Michele D Vos1, Alfredo Martinez, Chad A Ellis, Teresa Vallecorsa, Geoffrey J Clark.   

Abstract

Ras oncoproteins mediate multiple biological effects by activating multiple effectors. Classically, Ras activation has been associated with enhanced cellular growth and transformation. However, activated forms of Ras may also inhibit growth by inducing senescence, apoptosis, and differentiation. Induction of apoptosis by Ras may be mediated by its effector RASSF1, which appears to function as a tumor suppressor. We now show that the Ras effector Nore1, which is structurally related to RASSF1, can also mediate a Ras-dependent apoptosis. Moreover, an analysis of Nore1 protein expression showed that it is frequently down-regulated in lung tumor cell lines and primary lung tumors. Like RASSF1, this correlates with methylation of the Nore1 promoter rather than gene deletion. Finally, re-introduction of Nore1, driven by its own promoter, impairs the growth in soft agar of a human lung tumor cell line. Consequently, we propose that the Ras effector Nore1 is a member of a family of Ras effector/tumor suppressors that includes RASSF1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12676952     DOI: 10.1074/jbc.M211019200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Growth and tumor suppressor NORE1A is a regulatory node between Ras signaling and microtubule nucleation.

Authors:  Christine Bee; Anna Moshnikova; Christopher D Mellor; Justin E Molloy; Yulia Koryakina; Benjamin Stieglitz; Andrei Khokhlatchev; Christian Herrmann
Journal:  J Biol Chem       Date:  2010-03-25       Impact factor: 5.157

2.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Authors:  Sreenath V Sharma; Patrycja Gajowniczek; Inna P Way; Diana Y Lee; Jane Jiang; Yuki Yuza; Marie Classon; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  Release of RASSF1C from the nucleus by Daxx degradation links DNA damage and SAPK/JNK activation.

Authors:  Daiju Kitagawa; Hiroaki Kajiho; Takahiro Negishi; Seiji Ura; Tomomi Watanabe; Teiji Wada; Hidenori Ichijo; Toshiaki Katada; Hiroshi Nishina
Journal:  EMBO J       Date:  2006-06-29       Impact factor: 11.598

4.  Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways.

Authors:  Aparna Kaul; Jean H Overmeyer; William A Maltese
Journal:  Cell Signal       Date:  2006-11-28       Impact factor: 4.315

5.  Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma.

Authors:  Guang-yi Shan; Zhe Zhang; Qi-guang Chen; Xiu-yue Yu; Guo-bin Liu; Chui-ze Kong
Journal:  Tumour Biol       Date:  2012-01-17

Review 6.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

7.  Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors.

Authors:  Chang Kyun Lee; Jin-Hee Lee; Min-Goo Lee; Seong-In Jeong; Tae-Kyu Ha; Min-Ju Kang; Byung-Kyu Ryu; Young Hwangbo; Jae-Jun Shim; Jae Young Jang; Kil Yeon Lee; Hyo Jong Kim; Sung-Gil Chi
Journal:  BMC Cancer       Date:  2010-10-22       Impact factor: 4.430

8.  Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras.

Authors:  Maria Praskova; Andrei Khoklatchev; Sara Ortiz-Vega; Joseph Avruch
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

9.  Comparative analysis of interactions of RASSF1-10.

Authors:  Jia Jia Chan; Delphine Flatters; Fernando Rodrigues-Lima; Jun Yan; Konstantinos Thalassinos; Matilda Katan
Journal:  Adv Biol Regul       Date:  2013-01-11

10.  Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).

Authors:  Katy Hanlon; Claudius E Rudin; Lorna W Harries
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.